[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-healthy-adults\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-healthy-adults":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100603712",false,"NCT07140081","A Research Study to Evaluate BLX-0871 in Healthy Adults","A Phase 1 Randomized, Double-blind, Placebo-controlled Single-ascending Dose and Multiple-ascending Dose (SAD and MAD) Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Isoform-specific AMPK Activator BLX-0871 in Healthy Adults With a Body Mass Index (BMI) of 20 - 35 kg\u002Fm2","Inclusion Criteria:\n\n* Healthy males or females, 18-65 years, BMI 20-35 kilograms\u002Fmeter² (kg\u002Fm²), weight ≥50 kilograms (kg).\n* Normal or clinically acceptable labs, vital signs\n* HbA1c \\\u003C6.5%, non-fasting glucose 4.0-7.8 milimol\u002FLiter (mmol\u002FL)\n* Willing to follow contraception requirements, avoid alcohol, nicotine, and blood donation per protocol, and comply with all study visits and procedures.\n\nExclusion Criteria:\n\n* History of diabetes, clinically significant cardiovascular, hepatic, renal, gastrointestinal, psychiatric, or neurologic disease, or abnormal labs\u002FEchocardiograms (ECG) deemed clinically relevant.\n* Prior gastrointestinal (GI) surgery affecting absorption (e.g., gastric bypass) or chronic GI disorders.\n* History or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2); malignancy within 5 years (except treated basal cell or in situ cervical cancer).\n* History of severe allergic reactions, seizures, or psychiatric hospitalization; positive drug, alcohol, or cotinine test.\n* Use of prescription drugs, Over the counter (OTC) \u002Fherbal supplements\n* Participation in another clinical trial or blood donation within 30 days (or 5 half-lives of prior drug).\n* Any condition or history that may compromise safety, study conduct, or compliance, in the opinion of the Investigator.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},76,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance. The main goal is to see if BLX-0871 is safe and well tolerated when given to healthy adults. The study will also measure how the body processes BLX-0871, including how quickly it is absorbed, how long it stays in the blood, and how it is eliminated. Another objective is to see whether food affects the absorption of BLX-0871. It will also look at how the drug affects the body by looking at markers of AMPK activity.",[27],"Normal Healthy Adults",[29,30,31,32,33],"BLX-0871","0871","Obesity","Metabolic disorders","Normal health volunteer","NOT_YET_RECRUITING","2025-08-22",{"date":37,"type":38},"2025-08-24","ACTUAL",{"date":40,"type":21},"2025-09",{"date":42,"type":21},"2026-05",{"name":44,"class":45},"Biolexis Therapeutics","INDUSTRY",""]